Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 13;17:418. doi: 10.1186/s12967-019-02170-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — The FXR agonist GW4064 improved fasting blood glucose and inhibited the translocation of PGC1α and FOXO1 from the nucleus to the cytoplasm in gluconeogenesis with FK506 treatment in mice for 3 months. a After FK506 was administered at a dose of 1 mg/kg/day to the C57BL/6J mice for 3 months, the fasting blood glucose levels obviously increased gradually compared with those of the control group, and the FXR agonist GW4064 downregulated the blood glucose levels. No significant difference was found for b body weights and c morphological alterations among the control group, the FK506 group and the FK506 + GW4064 group. The C-1, C-2 and C-3 groups were the control group, the FK506 group and the FK506 + GW4064 group, respectively. d, f–h, j, k Western blotting and quantitative analysis show the protein subcellular localization of PGC1α and FOXO1. Original magnification, ×3400 in each group. e, i IF staining for PGC1α (e) and FOXO1 (i) in sections of 3 groups. DAPI was used to locate the nuclei of the cells. Data are presented as the mean ± SD (n = 7). *P < 0.05 vs. the control group, #P < 0.05 vs. the FK506 group